2021 MRR Symposium and Workshop

Join us for our first virtual MRR Symposium and Workshop. The first half day will consist of technical presentations that will provide perspectives on using MRR technology for industrial chemicals, drug development and synthesis, deuteration, molecular structural characterization, and spirits.

The second half day will provide attendees a unique opportunity to learn the fundamentals of MRR with tutorial lectures followed by a live demonstration of the instrumentation.

Dates: March 30-31, 2021
Symposium: Tuesday, March 30, 9 AM – 12 PM EST
Workshop: Wednesday, March 31, 9 AM – 12 PM EST

Agenda Day 1

09:00-09:30Molecular Rotational Resonance (MRR) – A Powerful Analytical Technique for Industrial Chemistry
Reinhard Doetzer, BASF
09:30-10:00Application of Molecular Rotational Resonance (MRR) Spectroscopy in Drug Development
Ted Chen, GSK
10:00-10:30Organalytical Chemistry: Development and Applications of Novel Analytical Methods to Support Organic Synthesis
Leo Joyce, Arrowhead Pharmaceuticals
10:30-11:00Synthesis and Characterization of Selectively Deuterated Small Molecules
Joe Clarke, Marquette University
11:00-11:30Eliminating Uncertanity in the Molecular Characterization of Small Molecules
Thomas Williamson, UNC Wilmington
11:30-12:00A Real-Time Technique for Analyzing Congeners
Robin Felder, University of Virginia
Organalytical Chemistry: Development and Applications of Novel Analytical Methods to Support Organic Synthesis

Agenda Day 2

09:00-09:45Theoretical Introduction to Rotational Spectroscopy and MRR Instrumentation
Justin Neill, BrightSpec
09:45-10:30Spectral Interpretation for Applied Molecular Rotational Resonance Spectroscopy
Reilly Sonstrom, BrightSpec
10:30-11:45Live Demonstration of MRR Technology
Alex Mikhonin & Don Cannon, BrightSpec
All Instructors
Organalytical Chemistry: Development and Applications of Novel Analytical Methods to Support Organic Synthesis

Invited Speaker Profiles

Joe Clarke, Marquette University

Joseph Clark was born and raised in Rochester, NY. In 2008, he graduated from St. John Fisher College with a B.S. in chemistry and completed a Ph.D. in June of 2014 working under Professor Steven T. Diver at the University at Buffalo. He worked as a NIH Ruth Kirschstein Postdoctoral Fellow under the direction of Professor M. Christina White at UIUC. Joseph joined the chemistry faculty at Marquette University in August of 2018 as an assistant professor. His research group works on developing new catalytic methods for the precise installation of deuterium into small organic molecules.

Leo Joyce, Arrowhead Pharmaceuticals

Leo Joyce is currently a Senior Chemist III in the Analytical Development department at Arrowhead Pharmaceuticals in Madison, Wisconsin.  Leo began his academic career researching small molecule synthesis as an undergraduate at the University of Wisconsin-Madison.  He went on to get a PhD in Organic Chemistry from the University of Texas at Austin, developing assays based on physical organic principles to rapidly determine enantiomeric excess in Professor Eric Anslyn’s lab.  Following graduate studies Leo joined the Analytical Research and Development department at Merck & Co in 2012, before leaving for Arrowhead Pharmaceuticals in 2019. Leo has spent his whole independent career working at the interface of organic and analytical chemistry, both with industrial scientists and through a myriad of academic collaborations.

Reinhard Doetzer, BASF

Reinhard Doetzer PhD is the senior principal scientist for hyphenation & structural elucidation at BASF’s competence center for analytics. He received his doctorate in organic chemistry from the Friedrich-Alexander-Universität Erlangen-Nürnberg and then completed a post-doc position at Princeton University under E.C. Taylor.  For the past 30+ years, Reinhard has worked for BASF holding various positions: leader for discovery synthesis fungicides, leader of spectroscopic structure elucidation for crop protection, and was appointed to principle scientist in 2009. 

Robin Felder, University of Virginia

Robin A. Felder PhD is a Professor of Pathology and Associate Director of Laboratory Medicine at The University of Virginia.  He is also Master Distiller and Farmer at Monte Piccolo Farm and Distillery.  He has published over 300 papers, reviews and chapters, co-edited 3 textbooks on medical automation, and founded the leading journal on laboratory automation. He has been awarded 27 patents and has founded 9 biotech companies, including 2 non-profit organizations including the Association for Laboratory Automation as well as Medical Automation.org.  He received his PhD in Biochemistry from Georgetown University and completed his post doc at the NIH.  He has received numerous awards including the Engelberger Robotics Award, UVA’s first Innovator of the Year, and the Annual Research Awards from the American Association for Clinical Chemistry, and National Academy for Clinical Biochemistry. He was recently inducted as Fellow of the National Academy of Inventors. At Monte Piccolo Distillery, he is currently creating novel fruit eau-de-vie style brandies as well as varietal gins™.

Ted Chen, GSK

Dr. Chen obtained his B.Sc. (Honors) from the University of Liverpool, and his Ph.D. in Organic Chemistry from the University of Manchester, both in England.  He then did a postdoc at the University of Iowa in Natural Products.  He has been with GSK for 35 years, as a Team Leader in Drug Substance and Product Analysis, located in Collegeville, Pennsylvania, engaging in small molecule drug development in the API space.  Dr. Chen has led 6 very successful NDAs.

Thomas Williamson, UNC Wilmington

Dr R. Thomas Williamson received his Ph.D. in Medicinal Chemistry from Oregon State University in 2000 under the direction of Dr. William H. Gerwick and joined Merck & Co. Inc. in 2011 after spending 4 years with Wyeth and 7 years with Roche. At Merck, Thomas served as Director of the Structure Elucidation Group where he oversaw the NMR and higher-end mass spectrometry technologies and their support of projects in Rahway, NJ, Kenilworth, NJ, Summit, NJ, Boston, MA, South San Francisco, and West Point, PA. Thomas’ work at Merck encompassed all phases of drug discovery and development, from lead identification and technology development through involvement in clinical development teams, and troubleshooting of manufacturing problems. During his tenure at Merck, Thomas was also a staunch advocate for the application of all kinds of new & emerging technologies to the solution of pharmaceutical problems and managed an annual capital instrument budget approaching $150,000,000. In late 2018, Thomas translated this industry experience to an academic setting at the University of North Carolina Wilmington where he was named the Yousry and Linda Sayed Distinguished Professor of Chemistry & Biochemistry. Thomas’ research group holds a special interest in marine natural products drug discovery, the elucidation of the structure and stereochemistry of complex molecules by NMR and the design of NMR pulse sequences to help achieve these goals. During his career, Thomas has published more than 130 peer-reviewed journal articles, seven book chapters, and has been invited to present the results of his cutting-edge research at various venues all over the globe.

For further information please contact:

Christopher Thompson
Director of Business Development
BrightSpec, Inc.
Email: chris.thompson@brightspec.com